| ATRX | α-thalassemia/mental retardation syndrome X-linked |
| BBB | blood–brain barrier |
| BV | blood vessels |
| CGP | chemical and genetic perturbations |
| CL | classical |
| FFPE | formalin-fixed paraffin-embedded |
| CP | canonical pathways |
| GSEA | gene set enrichment analysis |
| GBM | glioblastoma |
| GBMwt_hi | a subgroup of IDH wild-type tumors with a high content of CD45+ cells (more than 15% of the cellular suspension) |
| GBMwt_lo | a subgroup of IDH wild-type tumors with a low content of CD45+ cells (less than 15% of the cellular suspension) |
| IBA1 | ionized calcium binding adaptor molecule 1 |
| ICI | immune checkpoint inhibitors |
| IDH1/2 | isocitrate dehydrogenase 1/2 |
| IHC | immunohistochemistry |
| LGG | lower-grade glioma |
| MDSC | Myeloid-derived suppressor cells |
| MES | mesenchymal |
| MGMT | O6-methylguanine-DNA-methyltransferase |
| mut | mutant |
| ns | not significant |
| PCR | polymerase chain reaction |
| PD-1 | programmed cell death 1 |
| PD-L1 | programmed death ligand 1 |
| PN | proneural |
| RT | room temperature |
| SEM | standard error of the mean |
| TCGA | the cancer genome atlas |
| TME | tumor microenvironment |
| Tregs | regulatory T cells |
| VEGF | vascular endothelial growth factor |
| wt | wild-type |